Back to Journals » ClinicoEconomics and Outcomes Research » Volume 12

The Cost-Effectiveness of Universal Varicella Vaccination in Italy: A Model-Based Assessment of Vaccination Strategies

Authors Azzari C, Baldo V, Giuffrida S, Gani R, O'Brien E, Alimenti C, Daniels VJ, Wolfson LJ

Received 13 September 2019

Accepted for publication 16 February 2020

Published 8 June 2020 Volume 2020:12 Pages 273—283

DOI https://doi.org/10.2147/CEOR.S229685

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Professor Samer Hamidi


C Azzari,1 V Baldo,2 S Giuffrida,3 R Gani,4 E O’Brien,5 C Alimenti,6 VJ Daniels,7 LJ Wolfson7

1Department of Health Sciences, University of Florence and Meyer Children’s University Hospital, Florence 50139, Italy; 2Hygiene and Public Health Unit Department of Cardiac Thoracic Vascular Sciences and Public Health University of Padua, Padua 35100, Italy; 3LHU Reggio Calabria, Reggio 89100, Calabria, Italy; 4Evidence Synthesis, Modeling & Communication, Evidera, London, UK; 5Evidence Synthesis, Modeling & Communication, Evidera, San Francisco, CA, USA; 6MSD Italy, Market Access, Roma, Italy; 7Center for Observational and Real-World Evidence, Merck & Co., Inc., Kenilworth, NJ, USA

Correspondence: LJ Wolfson
Merck & Co., Inc., Center for Observational and Real-World Evidence (CORE), 600 Corporate Drive, CRB-205, Kenilworth, NJ 08833, USA
Tel +1 267-305-0650
Email lara.wolfson@merck.com

Background: In 2017, varicella vaccination became mandatory for all children in Italy, based on a two-dose schedule administered at 12– 15 months of age and 5 to 6 years of age. Varicella vaccines are available in different formulations (as a single vaccine or as a combination vaccine together with measles, mumps, and rubella) and are made by multiple manufacturers with different effectiveness profiles. This study calculates the cost-effectiveness of a range of varicella vaccination strategies to identify the optimal strategy for Italy.
Methods: A dynamic transmission cost-effectiveness model was applied in Italy to simulate the long-term (50 years) costs and outcomes associated with different varicella vaccination strategies. Five vaccination strategies were evaluated using the model: two doses of two different combination Measles-Mumps-Rubella-Varicella vaccines (either Vaccine A (MSD) [denoted QQVa] or Vaccine B (GSK) [denoted QQVb]); a first dose of a single Varicella vaccine followed by a second dose of a combination vaccine (either Vaccine C (MSD) followed by Vaccine A [denoted MQVa] or Vaccine D (GSK) followed by Vaccine B [denoted MQVb]); or no vaccine at all (NV). The model was adapted for Italy using publicly available Italian data and expert opinion.
Results: Over the 50-year time-horizon, in the absence of universal varicella vaccination, there would be 34.8 million varicella cases, 142 varicella-infection-related deaths, and € 23 billion in societal costs. The cost per capita from a societal perspective ranged from € 164.55 to € 392.18 with NV being the most expensive and QQVa the least expensive. The most effective strategy was QQVa, which resulted in a 66% decrease in varicella cases and 30% reduction in varicella-related deaths compared to NV strategy. QQVa led to a net saving in societal cost around € 13 billion compared to NV as the cost of vaccination was more than offset by the savings that resulted from the reduced burden of illness.
Conclusion: Varicella vaccination has a major impact on reducing varicella incidence, prevalence, and societal costs. This analysis supports the policy for universal varicella vaccination in Italy as the NV strategy was the most expensive and resulted in the poorest outcomes. QQVa offers the greatest benefits at the lowest cost and should be considered as a potential priority strategy for Italian population.

Keywords: varicella, vaccination, Italy, health-economics, cost-effectiveness, chickenpox, MMRV, varicella zoster virus

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]